Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients

International Journal of Urology

Volumn 17, Issue 12, 2010, Pages 980-987

  Kamba, Tomomi ^a   Kamoto, Toshiyuki ^c   Okubo, Kazutoshi ^a   Teramukai, Satoshi ^b   Kakehi, Yoshiyuki ^d   Matsuda, Tadashi ^e   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Outcome; Radiotherapy; Stage I seminoma; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; HUMAN; JAPAN; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; MULTICENTER STUDY; ORCHIECTOMY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEMINOMA; TESTIS; TESTIS CANCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649599450     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02645.x     Document Type: Article

References (27)

1. Martin JM, Panzarella T, Zwahlen DR, Chung P, Warde P. Evidence-based guidelines for following stage 1 seminoma. Cancer 2007; 109: 2248-56.
2. Classen J, Souchon R, Hehr T, Bamberg M. Treatment of early stage testicular seminoma. J. Cancer Res. Clin. Oncol. 2001; 127: 475-81.
3. Skliarenko J, Vesprini D, Warde P. Stage I seminoma: what should a practicing uro-oncologist do in 2009? Int. J. Urol. 2009; 16: 544-51.
4. Nakata S, Ohtake N, Kubota Y et al. Incidence of urogenital cancers in Gunma Prefecture, Japan: a 10-year summary. Int. J. Urol. 1998; 5: 364-9.
5. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol. 2003; 170: 5-11.
6. Miki T, Nonomura N, Saiki S, Kotake T. Long-term results of adjuvant irradiation or surveillance in stage I testicular seminoma. Int. J. Urol. 1998; 5: 357-60.
7. Sato A, Ohigashi T, Oya M et al. Clinicopathological features predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute. Urol. Int. 2006; 77: 64-8.
8. Yoshida T, Kakimoto K, Takezawa K et al. Surveillance following orchiectomy for stage I testicular seminoma: long-term outcome. Int. J. Urol. 2009; 16: 756-9.
9. Chung P, Mayhew LA, Warde P, Winquist E, Lukka H. Management of stage I seminomatous testicular cancer: a systematic review. Clin. Oncol. (R. Coll. Radiol.) 2010; 22: 6-16.
10. Lawrentschuk N, Fleshner N. Clinical stage I seminoma: the case for surveillance. World J. Urol. 2009; 27: 433-9.
11. Classen J, Souchon R, Hehr T et al. Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis. J. Cancer Res. Clin. Oncol. 2010; 136: 227-32.
12. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
13. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 2002; 20: 4448-52.
14. Aparicio J, Germa JR, Garcia del Muro X et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J. Clin. Oncol. 2005; 23: 8717-23.
15. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J. Clin. Oncol. 2004; 22: 640-7.
16. Reiter WJ, Brodowicz T, Alavi S et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J. Clin. Oncol. 2001; 19: 101-4.
17. Aparicio J, Garcia del Muro X, Maroto P et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann. Oncol. 2003; 14: 867-72.
18. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann. Oncol. 2008; 19: 443-7.
19. Peckham MJ, Brada M. Surveillance following orchidectomy for stage I testicular cancer. Int. J. Androl. 1987; 10: 247-54.
20. Dalal PU, Sohaib SA, Huddart R. Imaging of testicular germ cell tumours. Cancer Imaging 2006; 6: 124-34.
21. Kakehi Y, Kamoto T, Kawakita M, Ogawa O. Follow-up of clinical stage I testicular cancer patients: cost and risk benefit considerations. Int. J. Urol. 2002; 9: 154-60; discussion 160-1.
22. Albers P, Albrecht W, Albaga F et al. Guidelines on Testicular Cancer. [Cited 27 April 2009.] Available from URL.
23. NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer V.I. 2010. [Cited 10 May 2010.] Available from URL.
24. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J. Clin. Oncol. 2006; 24: 5503-11.
25. Francis R, Bower M, Brunstrom G et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur. J. Cancer 2000; 36: 1925-32.
26. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N. Engl. J. Med. 2007; 357: 2277-84.
27. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J. Urol. 2009; 181: 627-32; discussion 632-3.